Table 1. Demographic and clinical characteristics, comparing rosiglitazone to placebo in an 8-week study of clozapine-treated schizophrenia subjects (N=18).

	Placebo (N=10)		Rosiglitazone (N=8)		t	df	p
	Mean	SD	Mean	SD
Age, years	39.7	7.4	39.2	9.2	-0.1	16	0.91
Clozapine dose, mg/day	363	133	338	162	-0.4	16	0.72
Clozapine blood level, ng/mL	538	419	635	529	0.4	13	0.69
Norclozapine blood level, ng/mL	343	233	307	278	-0.3	13	0.79
	N	%	N	%	x2	df	p
Sex					0.06	1	0.81
Male	7	70	6	75
Female	3	30	2	25
Race					1.8	1	0.18
Caucasian	8	80	8	100
Hispanic	2	20	0	0
Alcohol use
Yes	2	20	1	12.5	0.18	1	0.67
No	8	80	7	87.5
Tobacco use
Yes	5	50	4	50	0.0	1	1.00
No	5	50	4	50
Family history of Cardiovascular disease
Yes	3	30	3	37.5	0.11	1	0.73
No	7	70	5	62.5
Family history of Hypertension
Yes	3	30	3	37.5	0.11	1	0.73
No	7	70	5	62.5
Family history of Diabetes
Yes	3	30	6	75	3.60	1	0.05
No	7	70	2	25